Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.31 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.31 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.31 |
| ▸ | MC4R | P32245 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16442476 | 0.85 | ALDH1A1 (0.36) | TSHRMAPK1PTGS1PTGS2 | |
| SCHEMBL22271746 | 0.84 | TSHR (0.39) | TSHRRORCPKMPTGS1PTGS2 | |
| SCHEMBL12172686 | 0.84 | TSHR (0.39) | TSHRRORCPKMPTGS1PTGS2 | |
| SCHEMBL24631600 | 0.82 | TAAR1 (0.36) | — | |
| SCHEMBL9284758 | 0.82 | TLR8 (0.35) | PTGS1PTGS2 | |
| SCHEMBL20685575 | 0.82 | NISCH (0.37) | TSHRRORCPDE2A | |
| SCHEMBL7881747 | 0.82 | TLR8 (0.35) | PTGS1PTGS2 | |
| SCHEMBL12686652 | 0.82 | MC4R (0.41) | TSHRRORCPKMPDE2AMC4R | |
| SCHEMBL12686634 | 0.82 | MC4R (0.41) | TSHRRORCPKMPDE2AMC4R | |
| SCHEMBL25974967 | 0.82 | MC4R (0.41) | TSHRRORCPKMPDE2AMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. | 2020-07-09 | — | — | US | disclosed |
| US-10308652-B2 | Tricyclic heterocyclic compounds useful as inhibitors of TNF | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-04 | — | — | US | disclosed |
| US-10189795-B2 | Aryl amine substituted quinoxaline used as anticancer drugs | Chen, Kuen-Feng (TW) | 2019-01-29 | — | — | US | disclosed |
| US-20180111937-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | BRISTOL MYERS SQUIBB CO (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170204071-A1 | ARYL AMINE SUBSTITUTED QUINOXALINE USED AS ANTICANCER DRUGS | SHIAU, CHUNG-WAI (TW) | 2017-07-20 | — | — | US | disclosed |
| EP-2922841-B1 | ALKYL-AMIDE-SUBSTITUTED PYRIDYL COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFN ALPHA RESPONSES | BRISTOL MYERS SQUIBB CO (US) | 2017-06-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10189795-B2 | Aryl amine substituted quinoxaline used as anticancer drugs | CIP2A, PPP2CA, PPM1A | TSHR 3848/4885RORC 4387/4885CASP1 3772/4885 |
| US-20180111937-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS INHIBITORS OF TNF | TNF, TNFRSF1A, TNFRSF9 | TSHR 125/4885RORC 444/4885CASP1 466/4885 |
| US-20170204071-A1 | ARYL AMINE SUBSTITUTED QUINOXALINE USED AS ANTICANCER DRUGS | CIP2A, PPP2CA, PPM1A | TSHR 3848/4885RORC 4387/4885CASP1 3772/4885 |
| US-10308652-B2 | Tricyclic heterocyclic compounds useful as inhibitors of TNF | TNF, TNFRSF1A, TNFRSF9 | TSHR 125/4885RORC 444/4885CASP1 466/4885 |
| US-20200216415-A1 | MELANOCORTIN SUBTYPE-2 RECEPTOR (MC2R) ANTAGONISTS AND USES THEREOF | MC3R, MC1R, MC2R | TSHR 102/4885RORC 316/4885CASP1 4853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.